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Less than one-third of HIV-infected pregnant women eligible for combination antiretroviral
therapy (ART) globally initiate treatment prior to delivery, with lack of access to timely CD4
results being a principal barrier. We evaluated the effectiveness of an SMS-based interven-
tion to improve access to timely antenatal ART.
Methods
We conducted a stepped-wedge cluster randomized trial of a low-cost programmatic inter-
vention in 20 antenatal clinics in Gaborone, Botswana. From July 2011-April 2012, 2 clinics
were randomly selected every 4 weeks to receive an ongoing clinic-based educational inter-
vention to improve CD4 collection and to receive CD4 results via an automated SMS plat-
form with active patient tracing. CD4 testing before 26 weeks gestation and ART initiation
before 30 weeks gestation were assessed.
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Results
Three-hundred-sixty-six ART-naïve women were included, 189 registering for antenatal
care under Intervention and 177 under Usual Care periods. Of CD4-eligible women, 100
(59.2%) women under Intervention and 79 (50.6%) women under Usual Care completed
CD4 phlebotomy before 26 weeks gestation, adjusted odds ratio (aOR, adjusted for time
that a clinic initiated Intervention) 0.87 (95% confidence interval [CI]0.47–1.63, P = 0.67).
The SMS-based platform reduced time to clinic receipt of CD4 test result from median of 16
to 6 days (P<0.001), was appreciated by clinic staff, and was associated with reduced oper-
ational cost. However, rates of ART initiation remained low, with 56 (36.4%) women regis-
tering under Intervention versus 37 (24.2%) women under Usual Care initiating ART prior to
30 weeks gestation, aOR 1.06 (95%CI 0.53–2.13, P = 0.87).
Conclusions
The augmented SMS-based intervention delivered CD4 results more rapidly and efficiently,
and this type of SMS-based results delivery platform may be useful for a variety of tests and
settings. However, the intervention did not appear to improve access to timely antenatal
CD4 testing or ART initiation, as obstacles other than CD4 impeded ART initiation during
pregnancy.
Introduction
To achieve the goal of elimination of mother-to-child transmission of HIV (MTCT), timely ac-
cess to combination antiretroviral therapy (ART) is vital for the 1.4 million HIV-infected
women who become pregnant annually [1]. When started before the third trimester of preg-
nancy ART reduces the risk of MTCT to 1–2% [2–10], even in breastfeeding populations [2].
ART is now recommended by the World Health Organization (WHO) for both maternal
health and for MTCT prevention for all pregnant and breastfeeding women [11].
Botswana and other countries in the region have made remarkable progress at improving
access to HIV testing and single-drug prevention of MTCT strategies [1,12]; however, access
to timely antenatal ART has lagged. Less than one-third of treatment-eligible women initiate
ART prior to delivery, with early antenatal CD4 testing being identified as a substantial barrier
[13–16]. Although no longer a requirement for starting ART in programs offering a life-long efa-
virenz-based ART regimens to pregnant women independent of disease stage (WHOOption B+)
[17], drawing a CD4 prior to ART initiation remains vital in countries such as Botswana where
CD4 testing is needed to guide whether ART should stop after MTCT prevention or continue
for maternal health (WHO Option B). In these settings delayed receipt of a CD4 test result
may be a bottleneck to the timely start of ART in pregnancy. In addition, timely CD4 enu-
meration is important to inform decisions for prophylaxis and evaluation for opportunistic
conditions.
Through key informant interviews and analysis of the prevention of MTCT cascade in a
large birth registry[18], we identified three principal obstacles for antenatal ART initiation in
Botswana: 1) difficulty completing CD4 phlebotomy during the first antenatal visit due to limi-
tations in supplies, staffing, and specimen transportation, 2) delay and unpredictability in the
return for CD4 test results from the central laboratory, and 3) challenges locating ART-eligible
women after receipt of CD4 test results. These treatment-eligible women, with CD4+ cell
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counts less than 350 cells/μL, account for greater than 80% of infant infections and an equal
proportion of maternal deaths [19]. Timely CD4 testing and initiation of ART can ameliorate
both risks[5,6,20,21].
Leveraging the potential of mobile health technology (mHealth) [22–25], we developed a
low-cost clinic-based intervention to address each of these three obstacles, including 1) partici-
patory provider education reinforcing protocols for CD4 testing, 2) an open source, automated
platform permitting monitoring and delivery of CD4 results via short message service (SMS)
between central laboratory and peripheral clinics, and 3) support for tracing women eligible for
ART initiation. We sought to evaluate whether this intervention improved timely CD4 testing
and ART initiation among HIV-infected, ART-naïve women in Botswana.
Methods
Ethics Statement
Officials and clinicians in charge of participating clinics provided written documentation of
permission. A waiver of informed consent was obtained to abstract routine clinical information
from patient obstetric and maternity records. All women participating in validation interviews
by study staff provided written informed consent. The study was reviewed and approved by
the Botswana Health Research Development Committee and the Institutional Review Board
of the Harvard School of Public Health. The trial clinicaltrials.gov registration number is
NCT01836003. Registration occurred after trial completion due to misunderstanding as to
whether a programmatic intervention should be registered and future trials would be regis-
tered. The protocol for this trial and supporting CONSORT checklist are available as support-
ing information; see S1 CONSORT Checklist and S1 Protocol.
Study Setting
The 20 highest volume antenatal clinics in greater Gaborone were included in this project,
which was named Tokafatso (‘improvement’ in Setswana, the local language). At the start of
the project in July 2011, each of these clinics provided antenatal care, onsite HIV testing and
counseling, and phlebotomy (or referral for phlebotomy) for CD4 enumeration. CD4 testing
and most deliveries occurred at the national referral hospital in Gaborone. At study start, clin-
ics received CD4 results via hand-delivered paper reports (9 clinics), electronic medical record
(EMR, 3 clinics), or travel to and transcription from an EMR-enabled clinic (8 clinics). Six clin-
ics had onsite ART services (not integrated with antenatal care activities), and 14 clinics re-
ferred offsite for ART initiation.
At the start of the project, women with a CD4 count of 250 cells/μL or less (or WHO stage
III/IV) were eligible for ART. Women with a CD4 count greater than 250 cells/μL received zi-
dovudine from 28 weeks gestation and single-dose nevirapine in labor [26]. A pilot program
was in place in 5 study clinics, which expanded ART eligibility to all pregnant women regard-
less of CD4 count. In this program, CD4 testing was required to direct ART regimen choice
and determine whether treatment would be continued after delivery. During the course of the
project, new national guidelines were released and gradually adopted by clinic staff beginning
in late 2012. These revised guidelines recommended ART for all HIV-infected women during
pregnancy and indefinite ART for women with a CD4 count of 350 cells/μL or less (or WHO
stage III/IV) [27,28]. While a CD4 result was not required for ART initiation following this re-
vision, clinicians generally still performed and waited for CD4 count results before starting
ART.
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Study Design
We conducted a cluster randomized study utilizing a ‘stepped wedge’ design [29,30]. This de-
sign was selected to ensure that all clinics could benefit from the Tokafatso intervention, permit
adjustment for time effects given evolving prevention of MTCT programs, and enable effective
implementation by a single study team. During the course of ten 4-week blocks between July
2011 and April 2012, all antenatal care clinics (ANCs) received the SMS-based intervention,
but the order of implementation was randomized. Clinics and the study team were blinded to
randomized order. One week prior to the start of a block, a randomization envelope was
opened revealing the names of the 2 clinics to receive the intervention during that block. Imple-
mentation was scheduled as close to the first day of the block as practicable. Once implementa-
tion occurred, the intervention remained in effect.
A 12-week lead-in period prior to implementation at the first clinics was planned. However,
a generalized public service strike leading to restricted health services limited this baseline peri-
od to 3 weeks. A follow-up period of 4-weeks was included after implementation in all clinics
for capture of additional pregnancies (Figs. 1 and 2).
Two randomly selected clinics (one pair) received the SMS-based intervention every 4
weeks from Period 2 to Period 11. Note: The sample sizes for each period and each clinic pair
are provided along the horizontal and vertical axes, respectively. The sample sizes for each clin-
ic pair are recorded for Usual Care, Transition, and Intervention in the colored bars.
Endpoints and Ascertainment
ART-naïve, HIV-infected Botswana citizens registering at a participating antenatal clinic prior
to 26 weeks gestation were included in the primary analysis. The primary study endpoints were
the proportion of HIV-infected, ART-naïve pregnant women a) completing phlebotomy for
CD4 enumeration by 26 weeks gestation and b) initiating ART by 30 weeks gestation. For anal-
yses related to CD4 testing, women with a CD4 result within 6 months of antenatal clinic regis-
tration were excluded as these women may not have been eligible for retesting.
Study endpoints were assessed through the abstraction of data from routine obstetric, ma-
ternity, and laboratory records at Princess Marina Hospital, the principal delivery ward for the
study antenatal clinics. Records of deliveries from June 2011 through October 2012 were re-
viewed. Gestational age was estimated from the date of the last normal menstrual period as re-
corded in the obstetric record. Gestational age at delivery was imputed from the population
median of eligible women for records with missing or unlikely (gestational age at delivery less
than 22 or more than 45 weeks gestation) dates.
For purposes of the analysis, a women was defined as being in the Intervention or Usual
Care period on the basis of whether the clinic was under usual care the intervention or usual
care at the time of her registration for antenatal care. Women first presenting for antenatal care
during the initial 4 weeks of the clinic receiving the intervention were assigned to Transition
period and not included in the primary analysis.
To assess accuracy and completeness of the abstracted information and to better understand
barriers to timely initiation of ART, a convenience sample on consenting HIV-infected women
delivering without a recorded CD4 result, or with a CD4 count of 250 cells/μL or less but not
on ART, were interviewed.
As designed, the study had estimated 90% power to detect an absolute 15% improvement in
CD4 testing by 26 weeks gestation (estimated baseline 36%) and a 35% improvement in rate of
ART initiation before 30 weeks gestation (estimated baseline 33%).
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Fig 1. Abstraction, eligibility, and analysis.Women could have more than one reason for ineligibility for the analysis.
doi:10.1371/journal.pone.0117181.g001
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Intervention
The Tokafatso intervention included an improvement package of augmented services around a
novel SMS-based platform for CD4 result distribution to antenatal clinics (Table 1). The pack-
age included the following:
a A 1–2 hour participatory session for clinic staff emphasizing the importance of timely CD4 test-
ing and ART initiation, and developing solutions to identified challenges to clinic performance
(e.g. result delivery, transportation, supply management, patient tracing, staff shortages).
b An automated SMS-based CD4 result platform that wirelessly distributed CD4 results to
portable SMS-enabled thermal printers (iBacsTel Electronics, Cardiff, United Kingdom) lo-
cated in each of the study antenatal clinics. The software was authored in Python (Python
Software Foundation, Wilmington, Delaware) over a MySQL database (Oracle, Redwood
City, California) using Django (Django Software Foundation, Lawrence, Kansas). The sys-
tem directly collected results from flow cytometer (FACSCalibur, BD, Franklin Lakes, New
Jersey) output files and integrated demographics and validation status from electronic rec-
ords. The system then sent valid results via an SMS gateway (Kannel, The Kannel Group,
Fig 2. Stepped-wedge implementation of the intervention by study period.
doi:10.1371/journal.pone.0117181.g002
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Helsinki, Finland) to printers in referring antenatal clinics. Results were printed as soon as
results were available. Clinic receipt of results was confirmed centrally via SMS, and modules
in system permitted central monitoring of parameters of clinic and laboratory performance
(e.g. alerts with testing frequency fell below expected ranges or when laboratory validation
results delayed). Clinic staff was required to ensure printers were adequately charged and
confirm that the printer had adequate paper. The Tokafatso system software is available of
free of charge (https://github.com/adrianveres/tokafatso).
c Longitudinal support by a study team member to antenatal clinics, including educating new
clinic staff, supporting SMS printers, assisting with supply outages (e.g. of HIV or CD4 test-
ing supplies), and proactively contacting clinics and the laboratory during periods of sus-
pected underperformance (e.g. responding to automated alerts). In addition, the study
personnel also reviewed ART-eligible cases with antenatal clinic staff, and provided airtime
to staff at antenatal clinics to contact all of these patients via mobile phone. The study team
obtained confirmation of successful patient contact by the antenatal clinic (see Fig. 3).
Table 1. Required steps to receive antenatal ART and description of Tokafatso intervention
activities.
Cascade Step Tokafatso Intervention Activities
Antenatal clinic registration None.
HIV testing Provision of HIV test kits through loans during periods
of supply outage.
CD4 phlebotomy Educational session (1–2 hours) and twice-monthly
contact with clinic to support early CD4 phlebotomy.
Provision of CD4 phlebotomy supplies through loans
during periods of supply outage.
Facilitated solutions to transportation challenges to
increase number of clinic days when CD4 phlebotomy
could be performed.
Central monitoring of CD4 testing frequency and
outreach to clinics with lower than expected test
frequency.
Laboratory processing of CD4 specimen Longitudinal monitoring of time to CD4 result
permitting real-time inquiries regarding delayed
results.
Clinic receipt of CD4 result Novel SMS-based platform that delivered results
directly to a printer in the antenatal clinic (typically at
desk of midwife) and provided chain-of-custody.
Patient receipt of CD4 results For each CD4  250 cells/μL the antenatal clinic was
contacted and provided with airtime to call patient and
request that she come to the clinic to receive results
and counseling.
ART clinic registration and baseline laboratory
testing
None.
ART adherence counseling, typically with a friend
or family member serving as an adherence
partner
None.
ART clinician evaluation and pick-up of ART
prescription
None.
Note: During the course of the project, receipt of a CD4 result became no longer formally required prior to
ART initiation. However, all clinic staff reported that they would not refer a patient to the ART clinic without
a CD4 count result. ART, combination antiretroviral therapy.
doi:10.1371/journal.pone.0117181.t001
SMS-Based Intervention for Antenatal ART
PLOSONE | DOI:10.1371/journal.pone.0117181 February 18, 2015 7 / 17
Operational Cost Estimation
The operational cost of delivering a CD4 result was estimated for the Tokafatso SMS-based
platform and for the three other modalities utilized for result distribution to the greater Gabo-
rone antenatal clinics. Operational costs of the Tokafatso platform were estimated through re-
view of time logs, transportation costs, and expenditures for SMS messages. Through
interviews with clinic staff we determined, for each cadre of the clinic staff, the monthly time
spent in CD4 result retrieval (reviewing paper or electronic records to find results), transport
to locations to retrieve CD4 results, and support of computerized systems. Salaries for each
cadre were estimated using representative salaries from the Botswana Harvard AIDS Institute
in Botswana. Fuel and vehicle costs were estimated at 1.75 pula per kilometer. Fixed infrastruc-
ture costs, including licensing and support fees to the provider of the government electronic
medical record system (MEDITECH, Westwood, Massachusetts), were not included. Cost per
CD4 result delivered was estimated from the total monthly cost related to CD4 delivery, total
number of CD4 results delivered, and the proportion of these results that were antenatal
CD4 results.
Fig 3. Mobile SMS printer in use. Printer is installed in an exam room of a study antenatal clinic.
doi:10.1371/journal.pone.0117181.g003
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Statistical Analysis
Comparisons of the study endpoints were performed utilizing general estimating equations
with adjustment for temporal effects and clustering at the clinic level following standard meth-
odology for stepped-wedge trials [30]. Small sample size precluded inclusion of individual 4-
week blocks, consequently temporal efforts were modeled using 12-week periods. The primary
models (Model A) accounted for clustering of participants within clinics and were adjusted for
the time that a clinic started the intervention. Findings in the primary models were assessed for
sensitivity to imputation strategy used for missing gestational ages, alternate group assignment
definitions, significant univariate predictors of endpoints, exclusion of individual clinics, and
different methods of modeling temporal effects. In addition, a secondary model (Model B) in-
cluding all factors identified as significantly associated with the endpoint was also fit to permit
adjustment for possible confounding. Analyses of time to testing or ART initiation were con-
ducted using marginal Cox models that incorporated the clinic-level clustering through the use
of robust sandwich covariance estimates [31].
Statistical analyses were performed with the use of the SAS statistical package, version 9.2
(SAS Institute, Cary, North Carolina). All tests were two-tailed and P-values of less than 0.05
were considered statistically significant.
Results
Study Clinics and Deliveries
A total of 19 of the 20 randomized antenatal clinics received the intervention. One antenatal
clinic had begun sending CD4 specimens to a different laboratory for analysis just prior to re-
ceipt of the intervention. As the clinic could not receive the SMS and patient tracing compo-
nents of the intervention, data from patients registering at this clinic after the change in CD4
testing were excluded.
During the study period, 2502 Botswana citizens registering at one of the study antenatal
clinics delivered at the principal maternity ward for these clinics. Of these, 726 were HIV-in-
fected (29.0%), 1769 (70.7%) were HIV-negative, and 7 (0.3%) had unknown HIV status. A
total of 239 (32.9%) HIV-infected women were already on ART prior to receiving antenatal
care. Of the remaining 487 ART-naïve women, 397 presenting for antenatal care prior to 26
weeks gestation without a CD4 count in the prior 6 months were included in the analyses. Of
these women 177 (44.6%) registered under Usual Care, 189 (47.6%) under Intervention, and
31 (7.8%) during Transition. The median gestational age at antenatal clinic registration was 18
weeks (Intervention 18 weeks, Usual Care 17 weeks, P = 0.30). The comparison groups were
well balanced in baseline characteristics (Table 2), except that women registering under Inter-
vention had less education and were more likely to receive care at a clinic with an on-site ART
clinic and early adoption of universal ART (WHO option B).
Primary Analyses
CD4 draw. Of ART-naïve, CD4-eligible women, 100 (59.2%) women registering at an ANC
during Intervention and 79 (50.6%) women registering during Usual Care completed CD4
phlebotomy prior to 26 weeks gestation. There was no significant difference between groups in
the primary analysis model (Model A) adjusting for clustering and temporal effects (adjusted
odds ratio (aOR) 0.87, 95% confidence interval [CI] 0.47–1.63, P = 0.67). Findings were similar
after additional adjustment (Model B) for possible confounders (Table 3). There were signifi-
cant temporal effects in both models (P<0.001) with overall improvement in the proportion of
women undergoing timely CD4 testing during the study period. During the first 3 months of
SMS-Based Intervention for Antenatal ART
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the study period—immediately following a protracted public employee strike—performance
under Usual Care clinics was poorer with 26.5% of women having CD4 by 26 weeks compared
with 69.3% during later periods. Registration to antenatal care later in pregnancy, unmarried
status, new HIV diagnosis in pregnancy, and presentation to a clinic with early implementation
of universal ART were each significantly associated with decreased odds of CD4 by 26 weeks
gestation.
ART Initiation. Among ART-naïve women, 56 (36.4%) women registering under Interven-
tion and 37 (24.2%) women registering under Usual Care initiated ART prior to 30 weeks
Table 2. Characteristics of ART-naïve, HIV-infected pregnant women and their antenatal clinics by
study group.
Characteristic Intervention N = 189 Usual Care N = 177
Maternal age (years), median
(quartiles)
28 (25, 33) 29 (26, 33)
Marital status, no. (%)
Married 17 (9%) 17 (10%)
Single/Divorced/Widowed 168 (89%) 157 (89%)
Unknown 4 (2%) 3 (2%)
Education, no. (%)
Primary or none 12 (6%) 16 (9%)
Secondary 157 (83%) 130 (73%)
University 15 (8%) 29 (16%)
Unknown 5 (3%) 2 (1%)
Imputed date of LNMP (missing or out-
of-range),a no. (%)
16 (8%) 10 (6%)
Gestational age (weeks) at ANC
registration, median (quartiles)
18 (14, 21) 17 (14, 21)
Gestational age (weeks) at delivery,
median (quartiles)
38 (36, 40) 38 (35, 40)
Premature delivery (< 37 weeks), no.
(%)
59 (31%) 61 (34%)
Timing of positive HIV test, no. (%)
Prior to pregnancy 53 (28%) 58(33%)
During pregnancy 131 (69%) 115 (65%)
After pregnancy/Unknown 5 (3%) 4 (2%)
CD4 count, no. (%)
 250 cells/μL 34 (18%) 32 (18%)
> 250 cells/μL 113 (60%) 99 (56%)
Missing 42 (22%) 46 (26%)
ANC with on-site ART clinic, no. (%) 89 (47%) 48 (27%)
ANC with on-site access to EMR, no.
(%)
25 (13%) 30 (17%)
ANC received early implementation of
universal ART, no. (%) b
78 (41%) 19 (11%)
Note: IQR, interquartile range; LNMP, last normal menstrual period; ANC, antenatal clinic; ART,
combination antiretroviral therapy; EMR, electronic medical record.
a Women with calculated gestational age less than 22 weeks or greater than 45 weeks were considered
likely out-of-range.
b Implementation of universal ART (WHO option B) prior to November 2011.
doi:10.1371/journal.pone.0117181.t002
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gestation. There were no significant differences in ART initiation prior to 30 weeks between In-
tervention and Usual Care in the primary analysis model (Model A)—aOR 1.06 (95% CI 0.53–
2.13, P = 0.87). Additional adjustment for possible confounders (Model B) produced similar re-
sults. There was also no significant difference in ART initiation prior to delivery between the
study groups, aOR 1.43 (95% CI 0.85–2.41, P = 0.18).
Impact on Specific Elements of the Prevention of MTCT Cascade. Rates of HIV testing
were high under both Intervention (99.7%) and Usual Care (99.6%), however rates of CD4 test-
ing and ART initiation remained low.
Timing of CD4 Phlebotomy. HIV-infected women eligible for CD4 enumeration were no
more likely to have a CD4 drawn within 1 day of registration if their clinic was under Interven-
tion or operating under Usual Care, 19.6% and 16.4%, respectively (P = 0.33). Time from ante-
natal clinic registration to CD4 testing was also not improved under Intervention versus Usual
Care (adjusted Hazard Ratio [aHR] 0.69, 95%CI 0.48–1.00, P = 0.05). Women registering
under the Intervention actually had significantly decreased odds of having a CD4 draw prior to
delivery compared with those registering during Usual Care periods (aOR 0.45, 95% CI 0.21–
0.94, P = 0.035).
Receipt of CD4 Results. Results from CD4 testing were obtained faster under the interven-
tion. Prior to implementation of the SMS-based platform for CD4 delivery, clinics obtaining
paper CD4 results reported a typical turn-around time of 17 days from sample draw to results
receipt at the clinic (range 7–35 days). Clinics with EMR access reported turn-around of 7 days
(range 3–14 days), and clinics needing to travel to an EMR-enabled clinic reported 14 days
(range 7–28 days). Weighting by proportion of results sent by each method, at baseline results
Table 3. Primary endpoints, timely CD4 phlebotomy and HAART initiation in eligible women.
CD4 phlebotomy before 26 weeks
gestation
ART initiation before 30 weeks
gestation
success/eligible (percent) success/eligible (percent)
Intervention Usual Care Intervention Usual Care
Success by period
Periods 1–3 0/4 (0%) 18/68 (26%) 0/5 (0%) 10/65 (15%)
Periods 4–6 17/36 (47%) 38 /51 (75%) 9/30 (30%) 18/52 (35%)
Periods 7–9 37/61 (61%) 22/36 (61%) 20/60 (33%) 8/34 (24%)
Periods 10–12 46 /68 (68%) 1/1 (100%) 27/59 (46%) 1/2 (50%)
Total 100/169 (59%) 79/156 (51%) 56/154 (36%) 37/153 (24%)
Odds Ratio (95% CI) P-value a Odds Ratio (95% CI) P-value a
Overall Effect Estimates
Women registering during Intervention versus Usual Care periods
Model A: adjusted for study period only 0.87 (0.47, 1.63) 0.67 1.06 (0.53, 2.13) 0.87
Model B: adjusted for study period and potential confounders 1.20 b (0.52, 2.78) 0.66 1.01 c (0.46, 2.22) 0.98
Note: ART, combination antiretroviral therapy; 95% CI, 95% confidence interval.
a Wald statistic.
b In addition to study period, adjusted for factors significant in univariate analysis: gestational age at antenatal registration, maternal marital status,
maternal level of education, timing of maternal HIV diagnosis (prior or during current pregnancy), whether antenatal clinic implemented universal ART
(WHO option B) prior to November 2011.
c In addition to study period, adjusted for factors significant in univariate analysis: gestational age at antenatal registration, maternal marital status, and
maternal age.
doi:10.1371/journal.pone.0117181.t003
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took a median of 16 days to reach clinics after CD4 phlebotomy. Under the SMS-based plat-
form, results were received by the antenatal clinic in a median of 6 days (interquartile range
[IQR] 3–7 days), significantly faster that under Usual Care (P<0.001, single sample Wilcoxon).
The SMS-based platform enabled more than 90% of ART-eligible women to be contacted by
the antenatal clinic and counseled to present for ART within 10 days of CD4 phlebotomy.
CD4 Phlebotomy to ART Initiation. CD4 testing prior to 26 weeks gestation was strongly
associated with ART initiation prior to 30 weeks gestation—aOR 7.48 (95% CI 3.69–15.1,
P<0.001). Registration under Intervention, however, was not significantly associated with de-
creased time from CD4 draw to ART initiation compared with Usual Care—aHR 0.89 (95%CI
0.60–1.31, p = 0.55). Time from clinic registration to ART initiation was also not significantly
different between groups in adjusted analyses (aHR 0.88 95% CI 0.56–1.37, p = 0.56).
Operational Cost
Labor expenses represented the majority of the operational costs for the Tokafatso SMS-based
platform and the existing CD4 result delivery methods employed in the study clinics. The num-
ber of staff hours (time spent by nurses, data clerks, drivers, computer technicians) required
was lower utilizing the Tokafatso system compared with existing methods, 0.26 versus 0.39
staff hours per CD4 result, respectively. The Tokafatso system delivered a CD4 result for an es-
timated $1.98 (lower $1.82, upper $2.14) per result delivered compared with an overall cost of
$2.73 (lower $2.56, upper $2.89) with standard delivery methods.
Interviews
Twenty postpartum, HIV-infected women who had received care at one of the study antenatal
clinics were approached and consented to be interviewed. Fifteen of these women were selected
for interview because they had no recorded antenatal CD4 measurement. The interviews con-
firmed that none of these women had received CD4 results, however 10 women (67%) reported
that blood had been drawn for CD4 but that they did not receive the results (clinic couldn’t lo-
cate results- 7, patient delivered prior to resulting- 2, patient couldn’t travel to clinic to collect-
1). Five (33%) women reported never having blood drawn for CD4 (verified no electronic re-
cord of CD4 draw).
Five women were selected for interview because they were eligible to start ART, but did not
initiate ART during pregnancy. Of these, 3 (60%) reported that could not start ART as the clin-
ic required them to have an adherence partner participate in counseling prior to initiation. One
woman reported that the ART clinic delayed starting for reasons that were not clear to her and
one women reported that she was not ready to accept treatment so soon after learning that she
was HIV-infected.
Midwives and HIV lay counselors from all 19 antenatal clinics that received the interven-
tion, and the regional prevention of MTCT coordinator, expressed that the intervention assis-
ted them with caring for HIV-infected pregnant women. There was strongest support for SMS
CD4 result platform and for the airtime provided to contact ART-eligible women. All clinics
expressed that they would like the project continued.
Discussion
In this prospective randomized trial, an augmented SMS-based programmatic intervention in
antenatal clinics did not improve timely CD4 testing or ART initiation among HIV-infected
pregnant women. The SMS-based CD4 result distribution platform led to considerable im-
provement in time to clinic receipt of results and was associated with reduced operational
costs. The intervention was well-received by clinic staff who perceived that it assisted in their
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care of HIV-infected pregnant women. However, the overall intervention was not associated
with clinical or performance improvement as measured by time to CD4 phlebotomy or
ART initiation.
The intervention was designed around the premise that early CD4 testing, prior to 26 weeks
gestation, was critical to timely ART initiation in pregnancy. Findings from this trial support
the notion that early CD4 testing is important (but not sufficient) for achieving this goal, with
women having a CD4 draw prior to 26 weeks more than 7 times more likely to start ART prior
to 30 weeks gestation. Unfortunately, only just over half of ART-naïve HIV-infected women
underwent phlebotomy by 26 weeks, and there was no significant difference in time to CD4
draw between Intervention and Usual Care. It is unclear why the intervention would have con-
tributed to the observed significant decrease in the odds of having a CD4 measured before de-
livery. While the SMS component of the intervention would not be expected to modify CD4
phlebotomy, the automated platform permitted real-time monitoring of testing volume and in-
terventions to ensure stable access to testing supplies and re-education of clinic staff on the im-
portance of CD4 testing at the first antenatal visit when testing volume dropped.
The second core premise of the intervention was that improving reliability and speed of
CD4 result return to the antenatal clinic would accelerate the process of ART initiation in preg-
nancy. The SMS-based platform succeeded in reducing time to CD4 result receipt by the clinic
and directing the result to the healthcare worker in the best position to act on the result. In ad-
dition, comments from clinic staff indicate that the intervention assisted with contacting and
engaging ART-eligible pregnant women. However, with improving this aspect of the cascade,
new obstacles to timely ART initiation were exposed. While we did not have access to utiliza-
tion data at the ART clinics, interviews with antenatal staff and patients indicated that travel to
the separate ART clinic and requirements for multiple visits for counseling and baseline labora-
tories were barriers, as has been observed elsewhere [32,33]. In the limited number of inter-
views of ART-eligible women who did not start ART, the need to complete counseling along
with a friend or family member serving as an adherence partner was the most frequently cited
reason for not starting ART in pregnancy. The intervention did not include activities facilitat-
ing care at the ART clinic or assisting with the disclosure of HIV status to a potential adherence
partner.
Applications of mHealth technologies have greatly expanded and have been cited as an asset
to public health programs in resource limited settings [34]. Like in this trial, many emerging
applications of mHealth are employed to circumvent physical or operational barriers in
strained healthcare systems. Prior successful uses of SMS for healthcare delivery have also fo-
cused on improving communication of clinical information across providers [24]. However,
the overall evidence in support of mHealth applications to improve healthcare delivery in re-
source-constrained settings is limited with few interventions evaluated rigorously for effective-
ness [35].
While direct-to-patient SMS programs has been shown in some settings to improve adher-
ence to ART[23,25,36,37], to our knowledge, this is the first randomized trial of an mHealth-
based intervention focusing on improving the cascade of activities necessary between HIV test-
ing and ART initiation. Our negative findings, therefore are important and should provide
valuable information to programs considering projects similar to those tested in this trial. It
highlights both the importance of systematic evaluation of mHealth programs against end-
points that are clinically relevant, and the limited ability of these technologies to overcome per-
sistent structural deficiencies in health systems. In our case, SMS messaging was an efficient
and effective solution for reducing time between CD4 testing at a central laboratory and receipt
of results at peripheral clinics. However, the intervention alone was not sufficient to address
the many complex structural and behavioral barriers to ART initiation among pregnant
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women. Our study is an example of how mHealth interventions can play an important role as
part of collaborative design frameworks, and how to evaluate interventions using discrete,
programmatically relevant outcomes of interest [38,39]. Future interventions that include
more robust programs to address remaining behavioral, educational, and clinic-based chal-
lenges to access may be more successful.
Promising alternatives to improving access to timely antenatal ART include strategies that
reduce the number and simplify the steps of the prevention of MTCT cascade. These include
point-of-care CD4 testing [40], decentralization of services to minimize transportation barriers
[41,42], and minimizing or removing repeated adherence counseling visits [32]. Such program-
matic changes have proven effective in scenarios like that recently established in Malawi that
initiate ART without measuring CD4 count or other baseline laboratory tests [43]. Another
promising strategy is to build longitudinal relationships with community-based lay health
workers who help navigate the cascade [44].
The rapid turnaround of CD4 tests—as well as other critical laboratories—remains an
important goal for ART programs throughout the developing world. In Botswana and other
Option B programs, a CD4 result is still required prior to starting ART to inform whether to
discontinue ART after delivery (or after breastfeeding) for women with CD4 greater than
350 cells/μL. CD4 enumeration remains important to clinical management in Option B+ and
during routine ART treatment. Additionally, reliable receipt of early infant HIV PCR results,
baseline or monitoring chemistries, cervical cancer screening results, and tuberculosis diagnos-
tics are large challenges for many HIV treatment programs. The SMS-based platform demon-
strated in this project successfully addressed laboratory turnaround and could have role to
improving systems. However, the findings of this study suggest that this implementation needs
to be tied to addressing remaining and emerging gaps in the health system.
The findings of this trial should be interpreted in the context of several important limita-
tions. The maternity data extraction captured information from fewer women than anticipated
and, following adjustment for clustering, the resulting confidence intervals for the effect esti-
mates are wide. While the evidence from the primary and secondary analyses consistently ar-
gues against a beneficial effect, due to the wide confidence intervals we cannot exclude a
clinically relevant difference. By chance, two large clinics serving a less educated population
and offering early universal ART were randomized to be the first pair to receive the interven-
tion. Consequently, the groups of women registering under Usual Care and under Intervention
differed in some baseline characteristics indicating possible bias. Despite multivariate adjust-
ment for these factors residual confounding is possible, although sensitivity analyses excluding
these clinics did not modify findings. In addition, some contamination between study groups
likely occurred with women receiving care from more than one ANC, or ANCs in transition
from usual care to intervention, and clinicians rotating between different ANCs. However, dif-
ferent study group definitions did not modify the findings and the most successful aspect of the
intervention—the automated SMS-platform—could only be accessed at intervention antenatal
clinics. Also, due to staged design only clinicians at intervention sites were aware that clinic
performance was being studied, possibly leading to increased motivation to improve care and
overestimating the positive effects of the intervention (i.e. Hawthorne effect). Although our re-
sults are most applicable to Botswana, the demonstration that rapid CD4 resulting to peripher-
al clinics is achievable through an SMS-based system is likely to be applicable to many low-
and middle-income country settings.
In conclusion, we found that a low-cost intervention involving clinic staff education and a
novel SMS-based CD4 result delivery and monitoring platform did not significantly improve
the proportion of women with antenatal CD4 testing by 26 weeks gestation or ART initiation
by 30 weeks gestation. However, this intervention did result in more rapid and less expensive
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CD4 resulting to peripheral antenatal clinics. This SMS-based platform may improve the speed





S1 Protocol. Trial protocol.
(PDF)
Acknowledgments
We would like to thank the staff of the participating antenatal clinics for their patience, cooper-
ation, and dedication to improve care for HIV-infected pregnant women. We are also indebted
to the contributions of the entire research staff at the Botswana Harvard AIDS Institute Part-
nership, in particular the steadfast assistance of Tapologo Leselwa and Dr. Joseph Makhema.
Author Contributions
Conceived and designed the experiments: SD-P MDH AV EvW KK RLS SL. Performed the ex-
periments: SD-P AV OJ RP MB CB BS EvWMM SM AAMM RLS SL. Analyzed the data: SD-
P KBMDH RP SL. Wrote the paper: SD-P KBMDH RPMS RLS SL.
References
1. World Health Organization, UNAIDS, UNICEF (2009) Towards universal access: scaling up priority
HIV/AIDS interventions in the health sector: progress report, November 2009. Geneva: World Health
Organization, UNAIDS, UNICEF. PMID: 25506961
2. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, et al. (2010) Antiretroviral regimens in pregnan-
cy and breast-feeding in Botswana. N Engl J Med 362: 2282–2294. doi: 10.1056/NEJMoa0907736
PMID: 20554983
3. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, et al. (2010) Maternal or infant
antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362: 2271–2281. doi: 10.1056/
NEJMoa0911486 PMID: 20554982
4. Kesho Bora Study G, de Vincenzi I (2011) Triple antiretroviral compared with zidovudine and single-
dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child
transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11: 171–
180. doi: 10.1016/S1473-3099(10)70288-7 PMID: 21237718
5. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, et al. (2009) Prevention of mother-to-child
transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar
es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 52: 406–416. doi: 10.1097/
QAI.0b013e3181b323ff PMID: 19730269
6. Peltier CA, Ndayisaba GF, Lepage P, van Griensven J, Leroy V, et al. (2009) Breastfeeding with mater-
nal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in
Rwanda. AIDS 23: 2415–2423. doi: 10.1097/QAD.0b013e32832ec20d PMID: 19730349
7. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, et al. (2011) Triple-antiretroviral prophylaxis to
prevent mother-to-child HIV transmission through breastfeeding—the Kisumu Breastfeeding Study,
Kenya: a clinical trial. PLoS Med 8: e1001015. doi: 10.1371/journal.pmed.1001015 PMID: 21468300
8. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. (2002) Combination antiretroviral strate-
gies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmis-
sion. J Acquir Immune Defic Syndr 29: 484–494. PMID: 11981365
9. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, et al. (2002) Two-dose intrapar-
tum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a ran-
domized trial. Jama 288: 189–198. PMID: 12095383
SMS-Based Intervention for Antenatal ART
PLOSONE | DOI:10.1371/journal.pone.0117181 February 18, 2015 15 / 17
10. European Collaborative Study (2005) Mother-to-child transmission of HIV infection in the era of highly
active antiretroviral therapy. Clin Infect Dis 40: 458–465. PMID: 15668871
11. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treatin-
gand preventing HIV infection: Recommendations for a public health approach. Geneva: World Health
Organization. doi: 10.1016/j.mgene.2013.11.003 PMID: 25612187
12. Gaolathe T, Tlale J, Keapoletswe K, Anderson MG, de la Hoz Gomez F, et al. (2008) Mother-to-Child
HIV Transmission Rate in Botswana—Analysis of Dried Blood Spot (DBS) Results from the National
PMTCT Programme. 4th IAS Conference on HIV Treatment, Pathogenesis and Prevention. Mexico
City.
13. KillamWP, Tambatamba BC, Chintu N, Rouse D, Stringer E, et al. (2010) Antiretroviral therapy in ante-
natal care to increase treatment initiation in HIV-infected pregnant women: a stepped-wedge evalua-
tion. Aids 24: 85–91. doi: 10.1097/QAD.0b013e32833298be PMID: 19809271
14. Chen JY, Ogwu AC, Svab P, Lockman S, Moffat HJ, et al. (2010) Antiretroviral treatment initiation
among HIV-infected pregnant women with low CD4(+) cell counts in Gaborone, Botswana. J Acquir Im-
mune Defic Syndr 54: 102–106. doi: 10.1097/QAI.0b013e3181c080bf PMID: 19864957
15. Mandala J, Torpey K, Kasonde P, Kabaso M, Dirks R, et al. (2009) Prevention of mother-to-child trans-
mission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers. BMC Pub-
lic Health 9: 314. doi: 10.1186/1471-2458-9-314 PMID: 19712454
16. van der Merwe K, Chersich MF, Technau K, Umurungi Y, Conradie F, et al. (2006) Integration of antire-
troviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic
Syndr 43: 577–581. PMID: 17031321
17. Interagency Task Team,World Health Organization, UNICEF (2013) Expanding and simplifying treat-
ment for pregnant women living with HIV: Managing the transition to Option B/B+. Geneva: World
Health Organization. doi: 10.1016/j.mgene.2013.11.003 PMID: 25612187
18. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, et al. (2012) Highly active antiretroviral therapy
and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 206: 1695–1705.
doi: 10.1093/infdis/jis553 PMID: 23066160
19. Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Mwiya M, et al. (2010) Potential impact of newWHO
criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission. AIDS 24: 1374–
1377. PMID: 20568677
20. Sterling TR, Chaisson RE, Keruly J, Moore RD (2003) Improved outcomes with earlier initiation of high-
ly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve du-
rable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 188: 1659–
1665. PMID: 14639536
21. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. (2008) Major clinical outcomes in antire-
troviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART
study. J Infect Dis 197: 1133–1144. doi: 10.1086/586713 PMID: 18476292
22. Howitt P, Darzi A, Yang GZ, Ashrafian H, Atun R, et al. (2012) Technologies for global health. Lancet
380: 507–535. doi: 10.1016/S0140-6736(12)61127-1 PMID: 22857974
23. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, et al. (2010) Effects of a mobile phone short message
service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet
376: 1838–1845. doi: 10.1016/S0140-6736(10)61997-6 PMID: 21071074
24. Seidenberg P, Nicholson S, Schaefer M, Semrau K, BweupeM, et al. (2012) Early infant diagnosis of
HIV infection in Zambia through mobile phone texting of blood test results. Bull World Health Organ 90:
348–356. doi: 10.2471/BLT.11.100032 PMID: 22589568
25. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, et al. (2011) Mobile phone
technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized
controlled trial of text message reminders. AIDS 25: 825–834. doi: 10.1097/QAD.0b013e32834380c1
PMID: 21252632
26. Botswana Ministry of Health (2008) Botswana 2008 National HIV/AIDS Guidelines, 1 November 2008
Edition. Ministry of Health, Botswana. PMID: 25506952
27. BotswanaMinistry of Health (2011) Prevention of Mother-to-Child Transmission (PMTCT) of HIV: Pock-
et Guide. Ministry of Health, Botswana. doi: 10.1080/17437199.2011.587961 PMID: 25473706
28. Botswana Ministry of Health (2012) 2012 Botswana National HIV & AIDS Treatment Guidelines. Minis-
try of Health, Botswana. doi: 10.1016/j.mjafi.2012.08.017 PMID: 25609874
29. Brown CA, Lilford RJ (2006) The stepped wedge trial design: a systematic review. BMCMed Res Meth-
odol 6: 54. PMID: 17092344
30. Hussey MA, Hughes JP (2007) Design and analysis of stepped wedge cluster randomized trials. Con-
temp Clin Trials 28: 182–191. PMID: 16829207
SMS-Based Intervention for Antenatal ART
PLOSONE | DOI:10.1371/journal.pone.0117181 February 18, 2015 16 / 17
31. Wei LJ, Lin DY, Weissfeld L (1989) Regression analysis of multivariate incomplete failure time data by
modeling marginal distributions. J Am Stat Assoc 84: 1065–1073.
32. Siedner MJ, Lankowski A, Haberer JE, Kembabazi A, Emenyonu N, et al. (2012) Rethinking the "pre" in
pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugan-
dans initiating ARVs. PLoS One 7: e39894. doi: 10.1371/journal.pone.0039894 PMID: 22761924
33. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, et al. (2010) Who starts antiretroviral therapy in Dur-
ban, South Africa?. . . not everyone who should. AIDS 24 Suppl 1: S37–44. doi: 10.1097/01.aids.
0000366081.91192.1c PMID: 20023438
34. World Health Organization (2011) mHealth: New horizons for health through mobile technologies: sec-
ond global survey on eHealth. Geneva: World Health Organization. doi: 10.1080/17437199.2011.
587961 PMID: 25473706
35. Tomlinson M, Rotheram-Borus MJ, Swartz L, Tsai AC (2013) Scaling up mHealth: where is the evi-
dence? PLoSMed 10: e1001382. doi: 10.1371/journal.pmed.1001382 PMID: 23424286
36. Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, et al. (2014) The use of cell phone support for
non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention
trial. AIDS Behav 18: 686–696. doi: 10.1007/s10461-013-0661-3 PMID: 24271347
37. Rodrigues R, Shet A, Antony J, Sidney K, Arumugam K, et al. (2012) Supporting adherence to antiretro-
viral therapy with mobile phone reminders: results from a cohort in South India. PLoS One 7: e40723.
doi: 10.1371/journal.pone.0040723 PMID: 22952574
38. Caldwell A, Young A, Gomez-Marquez J, Olson KR (2011) Global Health Technology 2.0. IEEE Pulse
2: 63–67. doi: 10.1109/MPUL.2011.941459 PMID: 21791404
39. Whittaker R, Merry S, Dorey E, Maddison R (2012) A development and evaluation process for mHealth
interventions: examples from New Zealand. J Health Commun 17 Suppl 1: 11–21. doi: 10.1080/
10810730.2011.649103 PMID: 22548594
40. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, et al. (2011) Effect of point-of-care CD4 cell count
tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an ob-
servational cohort study. Lancet 378: 1572–1579. doi: 10.1016/S0140-6736(11)61052-0 PMID:
21951656
41. Boyer S, Eboko F, Camara M, Abe C, Nguini ME, et al. (2010) Scaling up access to antiretroviral treat-
ment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS 24
Suppl 1: S5–15. doi: 10.1097/01.aids.0000366078.45451.46 PMID: 20023440
42. Bemelmans M, van den Akker T, Ford N, Philips M, Zachariah R, et al. (2010) Providing universal ac-
cess to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS
care. Trop Med Int Health 15: 1413–1420. doi: 10.1111/j.1365-3156.2010.02649.x PMID: 20958897
43. Centers for Disease C, Prevention (2013) Impact of an innovative approach to prevent mother-to-child
transmission of HIV—Malawi, July 2011-September 2012. MMWRMorb Mortal Wkly Rep 62: 148–
151. PMID: 23446514
44. Kim MH, Ahmed S, BuckWC, Preidis GA, Hosseinipour MC, et al. (2012) The Tingathe programme: a
pilot intervention using community health workers to create a continuum of care in the prevention of
mother to child transmission of HIV (PMTCT) cascade of services in Malawi. J Int AIDS Soc 15 Suppl
2: 17389. doi: 10.7448/IAS.15.4.17389 PMID: 22789644
SMS-Based Intervention for Antenatal ART
PLOSONE | DOI:10.1371/journal.pone.0117181 February 18, 2015 17 / 17
